United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesNasdaq
已确认可信度 83%The en banc opinion in No. 21-60626 is stamped "FILED December 11, 2024" and "Date Filed: 12/11/2024".[1]
The full US Court of Appeals for the Fifth Circuit voted 9-8 to vacate the SEC's approval of Nasdaq's rule requiring listed companies to have a woman and a minority or LGBTQ+ director on the board or explain why not.
已确认可信度 82%The opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
已确认可信度 83%The court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.